PDCD1 and melanoma: A phase 1 study testing anti-PD-1 blockade in combination with the VEGF inhibitor axitinib in 33 mucosal melanoma patients resulted in an ORR of 48% and a median PFS and OS of 7.5 and 20.7 months, respectively [110,111].